Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Therapeutic options to cure advanced, recurrent, and unresectable thymomas are limited. The most important factor for long-term survival of thymoma patients is complete resection (R0) of the tumor. We therefore evaluated the response to and the induction of resectability of primarily or locally recu...

Full description

Bibliographic Details
Main Authors: Lukas Kirzinger, Sandra Boy, Jörg Marienhagen, Gerhard Schuierer, Reiner Neu, Michael Ried, Hans-Stefan Hofmann, Karsten Wiebe, Philipp Ströbel, Christoph May, Julia Kleylein-Sohn, Claudia Baierlein, Ulrich Bogdahn, Alexander Marx, Berthold Schalke
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5161359?pdf=render

Internet

http://europepmc.org/articles/PMC5161359?pdf=render

Similar Items